Exicure (XCUR) Share-based Compensation (2016 - 2025)
Exicure's (XCUR) quarterly Share-based Compensation came in at $1000.0 in Q4 2025, down 83.33% YoY from $6000.0 in Q4 2024, and little changed on a QoQ basis from $1000.0 in Q2 2025.
Exicure (XCUR) Share-based Compensation (2016 - 2025) Analysis & Trends
Exicure (XCUR) has 10 years of Share-based Compensation data on file, last reported at $1000.0 in Q4 2025.
- Quarterly Share-based Compensation fell 83.33% year-over-year to $1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2000.0 (down 90.91% YoY) and the FY2025 annual result came in at $2000.0, down 90.91% from the prior year.
- Share-based Compensation held at $1000.0 in Q4 2025, from $1000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.2 million in Q4 2023 to a low of -$1.3 million in Q3 2021.
- A 5-year average of $81764.7 and a median of $6000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation tumbled 117.76% — and 2024, when it soared 100.43%.
- Tracing XCUR's Share-based Compensation over 5 years: stood at $5000.0 in 2021, then plunged by 17000.0% to -$845000.0 in 2022, then jumped by 245.09% to $1.2 million in 2023, then slumped by 99.51% to $6000.0 in 2024, then plunged by 83.33% to $1000.0 in 2025.
- The last three Share-based Compensation figures came in at $1000.0 (Q4 2025), $1000.0 (Q2 2025), and $6000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Exicure | 8.41 Mn | 8.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 1.23 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Sep 30, 2023 | -1.16 Mn |
| Sep 30, 2023 | -1.16 Mn |
| Jun 30, 2023 | 969,000.00 |
| Jun 30, 2023 | 969,000.00 |
| Mar 31, 2023 | 308,000.00 |
| Mar 31, 2023 | 308,000.00 |